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Stem Cells and Breast Cancer 
Hello. My name is Erin May, and I am a senior at Grand Valley State 
University.  I have been a member of the Honors College since my freshman 
year here at Grand Valley State University.  For my senior year project, I had 
decided to write an essay on something I am passionate about.  Stem cell 
research has become a crucial part of the science world, and during my genetics 
class my junior year, I had learned about tissue bioengineering.  This study 
sparked my curiosity with stem cells.  I researched many experiments that used 
the bioengineering of stem cells to produce new organs via organ printing.  I had 
no idea that this type of science was being used in an everyday setting.  It 
astounds me that even though I am a science major, and am greatly involved in 
research in my classes, how little I actually know about the miracles of stem 
cells.  Stem cells not only can build organs through organ printing, but they can 
be manipulated to cure diseases such as Parkinson’s disease, retinal diseases, 
diabetes, heart diseases and treat different cancers such as leukemia and breast 
cancer.  I want to share my experience of researching theories about stem cells 
and the many miraculous things they can do.  I want to describe my journey, my 
misconceptions about embryonic stem cells, and explain the stem cell therapies 
used to treat breast cancer.  
I am a Roman Catholic, and I am pro-choice.  I believe that inflicting my 
own religious and personal beliefs against others goes against the institution that 
America has instilled.  However, I personally am pro-life, because I would never 
consider an abortion if I were to become pregnant.  I believe life begins at 
conception, and ends with natural death.  I have a complex view about life, and 
about science.  I believe that stem cell research in all of its forms (embryonic, 
adult, and induced pluripotent stem cells) should be funded by the government, 
for it will allow scientists and researchers to continue the fight against chronic 
diseases and illnesses.  As a woman, a sister, and a potential mother, I want to 
see a cure for breast cancer during my lifetime.  I hope that my dream will 
become a reality.  Through my paper, I hope to recruit learned people to join the 
fight against breast cancer, to support more federal funding for stem cell 
research, and hopefully target common misconceptions that give stem cell 
research a tainted name. 
Breast cancer is the second leading cause of death in woman.  Metastasis 
(the rapid growing and mobility of a tumor), tumor relapse, and resistance to 
therapy are the main causes of death for breast cancer patients.  The lack of 
effective therapies calls for an improved understanding of the molecular 
mechanisms driving breast cancer progression.  In order to understand the 
multifaceted complexes of breast cancer research, there must be an 
understanding of stem cells, cancer stem cells, the breast, breast stem cells, and 
breast cancer stem cells.  Every tissue is composed of its own type of stem cells.  
Stem cells are homogeneous cells that have the ability to self-renew and 
separate into many types of mature cells such as tissue, muscle, and blood cells 
(Edgren).  Stem cells create new cells to replace older cells in the entire body.  
Without stem cells, our bodies would not be able to repair damaged cells.  Stem 
cells are described as pluripotent cells, which means they can become any type 
of cell in the human body.  A single stem cell can be differentiated (turned into) a 
tissue cell, or a blood cell, or a neural cell, depending on what the body needs.  
Pluripotent stem cells such as embryonic and induced pluripotent stem cells offer 
the possibility of a renewable source of replacement cells and tissues (Latfala). 
Stem cells are unique in their ability to divide and regenerate themselves and in 
their ability to remain specialized or unspecialized in the tasks of the human 
body.  Stem cells can be isolated and extracted from pluripotent embryonic cells, 
multipotent adult somatic cells, and induced pluripotent cells (genetically 
reversed adult somatic cells) to be used in clinical trials, and research methods. 
 Embryonic stem cells are the most successful type of stem cell to be used 
in the clinical setting.  They are prepared from embryonic tissues, primordial 
germ cells of late fetuses, and cord blood.  All of these reservoirs of these stem 
cells have multiple potentials, and allow the differentiation of haematopoietic 
(blood), neural, skeletal, muscle and other tissue cells.  Embryonic stem cells can 
become any cell in the three germ layers (ectoderm, mesoderm, and endoderm) 
and other specific tissues.  “Embryonic stem cells can be used as a vehicle for 
introducing targeted genetic modifications into the germ line (Solter).”  The gold 
standard for human embryonic stem cells is the cultures of the entire inner cell 
mass of the blastocyst.  
My initial concerns about embryonic stem cell research were similar to 
those who still oppose it today.  I believed that embryonic stem cell research 
involved the killing of a potential fetus.  I thought that scientists conned pregnant 
women into giving up their child’s life for science. I believed that scientists were 
killing potential fetuses in the process of retrieving embryonic stem cells.  The 
subject of stem cell research is difficult to understand at times, and if you as a 
reader have some trouble with this subject, or even this paper, I strongly suggest 
to do some research on your own.  Find answers to the questions you have, or 
talk to scholars of the field.  When I first started to write my paper, I had some 
misconceptions about stem cell research and my personal beliefs about it.  I met 
with Dean Hiskes, who is an extraordinary academic and has had many years 
working with stem cells, to discuss my opinions and concerns with the field.  She 
helped me shape my own opinions through understanding the facts about stem 
cell research, specifically regarding embryonic stem cells.  I encourage those 
who have questions about stem cells, or any subject that you are passionate 
about, to find the tenacity and curiosity that I had.  For you many find out, like I 
had, that my convictions were tainted by my lack of understanding.  
Embryonic stem cells are acquired mainly by two ways.  The first is by the 
fertilization of an egg with sperm (Latfala).  These embryos are obtained from the 
fertility clinics.  When couples are trying to have a baby through in vitro 
fertilization, they usually end up with far more fertilized embryos than they need 
or want.  Instead of throwing away the frozen embryos, the parents can donate 
their excess embryos to stem cell research.  I believe that this donation is a 
better use for the miracle of conception, than disregarding that miracle, and 
tossing the embryos in the trash to rot.  
The second method for obtaining embryos is through therapeutic cloning. 
In therapeutic cloning, the nucleus from one of the patient's cells is removed and 
merged with a donor egg, replacing the egg's natural nucleus (Edgren). That egg 
is then stimulated with chemicals or electrical energy designed to make it divide 
and replicate. Since its nucleus comes from the patient's own cell, the resulting 
cells should be accepted by the patient's body, meaning no rejection.  
Recently, it was discovered that embryonic stem cells can be obtained a 
third way.  Human embryonic stem cell line derivation does not necessarily 
require embryo destruction.  Biopsies from morula-stage embryos (the 
blastocyst, a hollow ball of cells during the first stage of fetal development from 
zygote) can derive multiple cell lines.  Scientists can use one cell line to take 
stem, which would allow the embryos to continue developing in vitro allow for the 
continual maturation of the embryo, without any defects (Edgren).  I believe that 
through this method of extracting embryonic stem cells from only one of the cell 
lines, the ethical concerns about embryonic stem cell research will become 
irrelevant, because the life of the embryo is being conserved.  However, this is a 
relatively new technique, so the ethical concerns of embryonic stem cell 
extraction still have a great influence on the availability of embryos for research.  
The only negative aspects of using embryonic stem cells are due to its very 
limited accessibility due to their ethical concerns, and their high risk of cancer 
formation.  One type of stem cell that does not have any of the ethical concerns 
surrounding its use in research is the adult stem cell.  
Adult stem cells can be found in bone marrow, skin, and other specific 
tissues of the body.  Adult stem cells can self-renew indefinitely, and generate 
the entire cell types of the organ from which they originate, which potentially 
regenerates the entire organ from a few cells. Although there are no ethical 
issues concerning adult stem cells, they have technical issues.  “The number of 
the stem cells in each tissue is generally so small that they require culture and 
expansion in vitro for the clinical use, because there is a critical difference 
between embryonic stem cells and adult stem cells in terms of growth (Okochi).”  
Adult stem cells undergo a rapid turnover rate to “replenish” any lost cells.  
Culturing adult stem cells requires specific conditions that are usually not 
satisfied.  The growth potential of adult stem cells is limited due to spontaneous 
differentiation of cells depending on their age and origin.  Adult stem cells have 
no risk of cancer formation, have an unlimited accessibility of stem cells, and 
need to be a high/full match for immune-compatibility.   Adult stem cells are 
useful in certain types of therapies such as bone marrow transplants (which will 
be discussed later in this paper).  However, I believe we will not find the cure for 
most diseases and illnesses with the use of adult stem cells.   
Induced pluripotent cells are somatic (any biological cell forming the body, 
for example a skin cell, a heart cell, or a lung cell) cells that were reversed into 
an immature cell state.  They are very similar to the pluripotent embryonic stem 
cells but do not carry with them the ethical concerns.  The ability to reprogram 
somatic cells to a pluripotent state offers tremendous potential for generating a 
source of patient specific pluripotent stem cells.  This is vital for the building of 
new organs through organ printing and treatment of illness and disease.  Patient 
derived induced pluripotent stem cells are expected to contribute both to treating 
the patient and do drug screening for the disease.  The induced pluripotent stem 
cells cell technology can be used for the production of cell lines from patients 
with various diseases (Turksen).  Several groups of somatic cells have shown 
potential to be reprogrammed to a pluripotent state: adult dermal fibroblasts, and 
epidermal keratinocytes.  “Any of these cell types may be suitable for large-scale 
construction of induced pluripotent stem cell lines and banks since harvest of 
these cells from adults can be accomplished via noninvasive or minimally 
invasive medical procedures (Palecek).”  Induced pluripotent stem cells lines 
should retain the ability to differentiate to any cell type in the adult, but the 
efficiency of differentiation may be varied based on the somatic cell source, 
donor age, or reprogramming method.  Induced pluripotent stem cells provide a 
new approach to the development of diseases based on a particular genetic trait 
at the cellular level. This method is not widely used; however, it may provide an 
alternative derivation method that reduces the ethical concerns associated with 
embryonic destruction.  Induced pluripotent stem cells have a limited accessibility 
of stem cells, have a high risk of cancer formation, and require a full match for 
immune compatibility. 
When comparing to adult stem cells, implantation of embryonic stem cells 
has a higher risk for spontaneous differentiation and can develop into cancer.  
One of the benefits of embryonic stem cells compared to adult stem cells is that 
there is no requirement for the cells to have immune capability.  Embryonic stem 
cells and induced pluripotent stem cells possess the ability to self-renew and 
differentiate into progenitor and terminal cells in each of the three embryonic 
germ layers: ectoderm, mesoderm, and endoderm.  Pluripotent stem cells offer 
the potential to serve as in vitro disease models (Okochi).  Long term 
applications of human pluripotent stem cells include serving as a source of cells 
for tissue engineering and regenerative medicine applications. Just as adult stem 
cells, pluripotent stem cells have their limitations and technical issues that 
impede the translation of pluripotent stem cell research to clinical therapies.  
Pluripotent stem cells have the ability to cause tumors that exhibit the three germ 
layers called teratomas inside the body, so methods to ensure products contain 
no undifferentiated cells will be critical.  However the limitations, induced 
pluripotent stem cells are becoming more and more preferred. 
Stem cells can be used to treat diseases through repairing its tissues to 
replacing disfigured cells in the tissues. Most stem cells are specific to the type of 
tissues they become.  For examples, hematopoietic stem cells are stem cells of 
bone marrow.  Hematopoietic (blood) stem cell transplantation is the oldest and 
most widely available stem cell therapy.  It is used to treat diseases such as 
leukemia (cancer of the blood or bone marrow), thalassaemias (inherited 
autosomal recessive blood disorders), sickle cell disease, and myeloid 
hypoplasia (anemia or neutropenia) (Nguyen).  Bone marrow transplants are the 
most used stem cell therapy because it is easily harvested, is a low risk to the 
donor, and does not need to be grown inside the patient before it is transplanted.  
This is because hematopoietic stem cells continually create all of the new 
differentiated hematopoietic cells in peripheral circulation, including leucocytes, 
erythrocytes, and thrombocytes.  Another common stem cell therapy is through 
the use of umbilical cord blood and mesenchymal stem cells. 
Umbilical cord blood contains the same kinds of hematopoietic stem cells 
as bone marrow.  Umbilical cord blood has already been used extensively for 
hematopoietic stem cell therapy and has been used to treat leukemia, 
hematological diseases and inherited metabolic diseases.   Mesenchymal stem 
cells (multipotent stromal cells) from bone marrow have been reported to play an 
important role in supporting the maintenance of hematopoietic stem cells.  
Mesenchymal stem cells are derived from the umbilical cord and the placenta 
that can divide into many different types of undifferentiated cells.  Mesenchymal 
stem cells are commonly used because they have a low risk of immune rejection 
when transplanted into a patient.  They have the potential to differentiate into 
many lines of mesenchymal tissue, such as bone, cartilage, fat, tendon, muscle, 
and ligament (Reya).  Mesenchymal stem cells along with hematopoietic stem 
cells can be used to treat disorders of the neurodegenerative and cardiac 
systems.  Mesenchymal stem cells are more promising to use instead of 
hematopoietic stem cells or even skeletal myoblasts because they can 
differentiate into cardiomyocytes and are less provocative to the immune system 
than hematopoietic stem cells. Experiments are still in progress to find the best 
cell therapy for neural and heart disease.  The gold standard for regenerating 
heart muscle so far is endogenous cardiac stem cells (Nguyen).  Although there 
are treatments and cures for certain illnesses and diseases, there is still no cure 
for cancer, and some treatments for certain cancers are available.  This is due to 
the complexity and unpredictability of cancer cells. 
Stem cells and cancer cells share the ability to self-renew.  Newly arising 
cancer cells appropriate the machinery for self-renewing cell division that is 
normally expressed in stem cells.  There has been evidence that shows the 
many pathways that are classically associated with cancer may also regulate 
normal stem cell development.  For most cancers, the target cell of transforming 
mutations is unknown.  There is considerable evidence that certain types of 
leukemia arise from mutations that accumulate in hematopoietic stem cells 
(Reya).   
Cancer stem cells arise from normal stem cells.  Several lines of evidence 
indicate that cancer stem cells can also arise from mutate progenitor cells.  
These can possess substantial replicative ability, but they do not usually have the 
self-renewal capacity of stem cells.  To become a cancer stem cell, a progenitor 
cell must acquire mutations that cause it to regain the property of self-renewal.  
Multiple pathways and processes can give rise to cancer stem cells.  A small 
subgroup of cells in a tumor is essential for its growth.  Cancer stem cells can be 
the source of all the malignant cells in a primary tumor.  They can compose the 
small reservoir of drug resistant cells that are responsible for relapse after a 
chemotherapy induced remission or they can give rise to distant metastases.  
The biologic feature of cancer stem cells in each of these instances may differ, 
suggesting that the acquirement of characteristics associated with tumor 
progression, such as genetic instability and drug resistance, will also be 
associated with cancer stem cells (Nguyen).  It is becoming evident that a cancer 
treatment that fails to eliminate cancer stem cells may allow regrowth of the 
tumor.  Therapeutic strategies that specifically target cancer stem cells should 
eradicate tumors more effectively than current cancer treatments and reduce the 
risk of relapse and metastasis. 
Cancer stem cells have been analyzed and compared to the cells present 
in different cancers.  Scientists have discovered that specific cancers have their 
own cancer stem cells that make that cancer unique.  However, in order to 
understand the cancer stem cells of a specific cancer, one must understand the 
organ or tissue that the cancer is attacking.  Understanding all the building blocks 
and connections between cancer and the body will help scientists target specific 
cancer cells, and leave the rest of the body unaffected (Nguyen). One major type 
of cancer experienced by 1 in 8 women in United States alone is breast cancer.  
So, in order to explore this topic of breast cancer further, an explanation of the 
human breast is necessary for making connections.  
The human breast is a complex secretory organ that is composed of an 
intricate diverging system of epithelial ducts surrounded by a fat pad, which is 
rich in adipocytes (fat cells), blood vessels, hematopoietic cells, and stromal 
fibroblasts.  The epithelial ducts are lined with an inner layer of luminal epithelial 
cells and an outer layer of contractile basal myoepithelial cells that promote the 
extrusion of the secreted milk from the alveoli during lactation.  These ducts also 
lay in the same area that houses other ducts that produce milk during lactation 
(Reya).  During pregnancy, hormones cause the development and differentiation 
of specific cells into secretory cells that produce and secret milk.  Once milk is 
not needed from the breast (the mother has stopped breast feeding), the 
expanded mammary duct is returned to its normal state through a process known 
as involution, which involves extensive apoptosis (programmed cell death) and 
tissue remodeling.  It is when the cells of the breast begin to act spontaneously 
and irregularly that cancer can be developed. 
Breast cancer is the third major human cancer in which cancer stem cells 
have been definitely identified.  Breast cancer stem cells have been recently 
identified and purified based on their surface antigen expression.  In metastatic 
(final step in malignancy) breast cancer, “cells with a specific cell surface antigen 
profile of CD44-positive and CD24 –negative could successfully establish 
themselves as a tumor (Jordan).”  This antigen profile has been closely studied 
and used in research labs to predict and target breast cancer.  It has been shown 
that purified CD44-positive and CD24-negative cells could differentiate and give 
rise to cells similar to those found in the major tumor population (May). The 
recognition of mammary epithelial stem cells has led to the hypothesis that these 
may be at the root of breast cancer.   
One theory proposes that breast cancer stem cells resulted from the 
deregulation of normal stem cell self-renewal and differentiation pathways, 
resulting in cancer cells with both self-renewal and differentiation capabilities.  
Evidence for this theory arises from the similarities between normal stem cells 
and cancer stem cells and that normal stem cells are highly susceptible to 
mutations and oncogenic transformation due to their long lifespans. Breast 
cancer stem cells are likely to originate from basal mammary stem cells due to 
the similarities between the surface profile of basal cells and the breast cancer 
stem cells they discovered.  
 The second theory suggests that breast cancer stem cells develop from 
epithelial-mesenchymal transition (abnormal activation of latent embryonic 
programming in stem cells).  Cells that undergone this are susceptible to 
transformation and have many characteristics and behaviors similar to those of 
normal and neoplastic stem cells (Jordan).  Epithelial-mesenchymal transition 
can establish cancer cells with the mobile and invasive capabilities associated 
with the fast movement of the cancer cells.  Tumor progression is driven by 
cancer stem cells that show the ability to self-renew and the ability to regenerate 
the phenotypic heterogeneity of parental tumor.  Cancer stem cells have been 
involved in starting and supporting primary tumor growth and in driving the 
formation of metastasis at different sites. 
 Breast cancer stem cells have the ability to self renew and a potential to 
differentiate, generating cells with a variety of phenotypes within tumors.  Another 
important feature of breast cancer stem cells is their ability to differentiate into 
non-stem breast cancer cells.  This occurs inside the body as well as under 
standard growth conditions in the lab.  Breast cancer stem cells can be derived 
from mammalian differentiated epithelial cells.  It has been found that retinoic 
acid plays a role in the control of self renewal versus differentiations of breast 
cancer stem cells.  ATRA, an inducer of retinoid signaling, decreases formation 
of cells in the mammary region and either induces genes expressed in 
differentiated breast cancer cells or down regulates several programs involved in 
breast cancer stem cell self-renewal (Jordan).  Genes may not have a causal 
relationship with breast cancer may still be correlated with outcome.  Therefore 
care must be taken when relating the prognostic value of a gene profile to the 
involvement of a molecular target in the progression of that disease.   
Breast cancer stem cells demonstrate resistance to chemotherapy and 
radiotherapy. The mechanisms of chemoresistance are thought to arise from 
metabolic quiescence, a high level of expression of anti-apoptotic proteins and 
the presence of multi-drug resistance transporters.  The drug resistance in breast 
cancer stem cells is associated with alteration in self-renewal at cell fate 
signaling pathways of the cells.  However, resistance is not a universal 
characteristic of breast cancer stem cells.  It can be depleted by radiotherapy.  
Specific targeting of these populations leads to a diminishing of cancerous breast 
stem cells.  Also, these resistant populations have been use in a number of 
chemotherapeutics used to treat breast cancer.  The proportion of CD44+CD24- 
cells was increased in breast cancer patients after treatment with 
chemotherapeutic drugs.  Of the 1% of cells that survived chemotherapy, 30-35% 
of them were CD44+CD24- cells (May).  Trastuzumab, an antibody composed of 
many identical cells, in particular has been used successfully to treat HER2-
positive, early and metastatic breast cancer.  It has been shown that the 
overexpression of the HER-2 gene is associated with estrogen receptor-negative 
characteristics in women. The HER receptors are proteins that are rooted in the 
cell membrane and give off molecular signals from outside the cell to inside the 
cell, and turn genes on and off. The HER proteins also stimulate cell production.  
In breast cancer HER2 is over-expressed, and causes cancer cells to reproduce 
uncontrollably (Reya).  It has been shown that trastuzumab improved overall 
survival for women with metastatic breast cancer.  In early stage breast cancer, it 
reduces the risk of cancer returning after surgery.  However it can cause serious 
heart problems which may resolve if treatment is stopped.     
 When used in combination with conventional chemotherapeutic drugs, 
trastuzumab results in a response rate of between 50 and 84% (Nguyen).  
However, the majority of patients develop resistance within one year of the start 
of treatment.  Resistance is thought to be at least in part due to the role of the 
cancer stem cell population.  The interaction between CD44 and hyaluron (a 
sugar that is widely distributed in connective, epithelial, neural tissues) and has 
been shown form a resistance to trastuzumab by interfering with the connection 
of the antibody to the Her2 receptor on the cell surface.  Trastuzumab is also 
being studied for the treatment of other cancers.  It has been used with some 
success in women with uterine papillary serous carcinomas that overexpress 
HER2/neu protein.  However, any treatment that risks the presence of a drug-
resistant population that can regenerate a tumor after treatment has serious 
consequences for therapy.   
Another therapy against breast cancer stem cells may be heat shock 
protein 90.  Heat shock protein 90 is a member of the group of proteins known as 
molecular chaperones, which act as facilitators and quality control factors for the 
correct folding, assembly and transport of nascent and mature proteins within the 
cell (Nyugen).  A number of anti-heat shock protein 90 drugs are currently being 
developed as anti-cancer agents.   
 The most important features of heat shock protein 90 as an anti-cancer 
target is the ability to simultaneously inhibit multiple-signaling pathways and its 
drug selectivity.  The selectivity of the drug is achieved by the specific 
characteristics of heat shock protein 90 function in cancer cells and stem cells.  
Heat shock protein 90 functions to exclusively control the folding and stability of 
numerous transcription factors and signaling intermediates inside the body, 
which includes some key regulators of breast cancer (Nguyen). The association 
of such a wide range of signaling receptors, intermediates and transcriptional 
mediators with the common chaperone, makes heat shock protein 90 an 
attractive target to simultaneously inhibit multiple cellular pathways in cancer.  
Many proteins that heat shock protein 90 control mediates fundamental cellular 
processes such as apoptosis, cell cycle, and cell proliferation and differentiation,  
many of which are essential to the establishment and survival of cancer and 
cancer stem cells.  Higher levels of heat shock protein 90 expressions have been 
observed in cancer cells and the inhibition of heat shock protein 90 has been 
linked to cancer and stem cell differentiation (Hanahan). 
 The inhibition of a number of these pathways through targeting of heat 
shock protein 90 is already being harnessed to develop anti-cancer agents.  In 
most cases, these drugs are selective for cancer cells, due to the fact that heat 
shock protein 90 is over-expressed into cancerous cells compared to normal 
cells. However, there is little known about the difference in the heat shock protein 
90  mediated signaling pathways in cancer stem cell compared to cancer cells or 
indeed, normal stem cells.  If there is no sufficient difference between heat shock 
protein 90 expression and function in normal stem cells compared to cancer stem 
cells, there is a risk that anti- heat shock protein 90 drugs may deplete the 
normal stem cell population that are essential for correct organ homeostasis.  
Comparative analysis of the biochemistry and cell biology of somatic and cancer 
stem cells populations should be essential component of these drug 
development programs. 
 Some information on cancer stem cells signaling has been obtained from 
studying the pathways that underlie the unique features of stem cells, such as 
self renewal.  Some of the else pathways are directly chaperoned by heat shock 
protein 90 while others are indirectly linked to heat shock protein 90 as they lead 
to downstream activation of intermediates of pathways that are chaperoned by 
heat shock protein 90 (Hanahan).   
 Gene therapy delivered directly to a particularly stubborn type of breast 
cancer cell causes the cells to self-destruct, lowers the chance of recurrence and 
helps increase the effectiveness of some types of chemotherapy.  Scientists 
have found in cellular and mouse studies the gene mutation BikDD significantly 
reduced treatment-resistant breast cancer stem cells by blocking the activity of 
three proteins in the GBcl-2 family (May).  This genetic approach increased the 
benefits of lapatinib, one of the most common chemotherapy drugs for HER2-
positive breast cancer (May). Lapatinib is an orally active drug used to treat 
breast cancer.  It is composed of two tyrosine kinase inhibitors which disrupt the 
HER2 protein.  It is used for the treatment of patients with advanced or 
metastatic breast cancer whose tumors over-expressed HER2 protein (May). 
 Another recent finding is that epithelial cells can be induced to take on 
stem cell properties by forcing them to undergo epithelial-mesenchymal 
transition.  This change from epithelial cells to mobile mesenchymal stem cells is 
an important step in metastasis.  During normal embryonic development, 
epithelial-mesenchymal transition serves to loosen cell to cell contacts and to 
enhance intrinsic cell motility, thus paving the way for the extensive cell 
movements required for gastrulation and organogenesis.  In normal adult tissues, 
the typically dormant epithelial-mesenchymal transition program is reactivated 
during wound repair and tissue regeneration.  Dysregulation of epithelial-
mesenchymal transition however can lead to pathologic conditions such as organ 
fibrosis and tissue destruction.  Non-metastatic cancer cells may harness the 
epithelial-mesenchymal transition program to attain the migratory and invasive 
potential required for metastatic progression.  
 There is increasing evidence of similar cellular hierarchies in the normal 
and malignant mammary gland.  The gene expression profile of CD44+/CD24 
breast cancer cells, enrich for cells with tumor-initiating capabilities more closely 
resembles that of CD44+/CD24 cells from the normal breast than CD44+/CD24 
cells isolated from the same tumor (May).  Breast cancers have long been 
recognized as a remarkably diverse and heterogeneous set of malignancies, 
owing mostly to their classification into numerous histological subtypes on the 
basis of several histopathological criteria.  In recent years, cytogenetic and 
mutational analyses- in conjunction with molecular profiling technologies- have 
revealed that this histologic heterogeneity is underpinned by diverse gene 
expression signatures, though to represent the different cell lineages of the 
mammary gland and stages of mammary epithelial cell differentiation.  Using 
genomic profiling at least six breast cancer intrinsic subtypes have been 
identified on the basis of their distinct molecular signatures rather than their 
clinical or histopathology behavior. 
 The findings that link epithelial-mesenchymal transition, cancer stem cell 
traits drug resistance and enhanced metastatic competence suggest that 
targeting the epithelial-mesenchymal transition and cancer stem cell phenotype 
may hold considerable therapeutic promise. The anti-diabetic drug metformin, 
which has long been recognized for its beneficial effects in breast cancer, was 
recently shown to selectively kill breast cancer stem cells inside the body (Reya).  
Moreover the combination of metformin and DNA damaging agent doxorubicin 
reduced tumor mass and prevented relapse more effectively than either drug 
alone.  Residual cell populations recovered from these tumors after the combined 
treatment were devoid of cancer stem cells demonstrating that the therapeutic 
prowess of metformin is linked to its ability to kill cancer stem cells.  The need to 
combine conventional chemotherapies, radiotherapies, or endocrine therapies 
with drugs targeting the self-renewal, survival and drug resistance of cells with an 
epithelial-mesenchymal transition and cancer stem cell phenotype is key to stop 
the progression of breast cancer (May). 
 Stem cell research has become an extremely important subject in our 
world.  Stem cells can help find cures and treatments for diseases and illnesses 
such as Parkinson’s diseases, leukemia, and even breast cancer.  Although 
there are some ethical concerns about stem cell research (embryonic stem cell 
research in particular), I hope that my paper has given insight to the miracles it 
can provide.  Through my own experiences that I have shared, I hope that my 
readers can relate and learn from my misconceptions.  The goal of this paper 
was to inform those who may not know a lot about stem cell research in hope 
that they may be educated citizens.  Ignorance is the foundation that bans stem 
cell research.  If ignorance is halted, cures for major diseases and illnesses can 
be discovered. 
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